CHEMICAL REMODELING OF THE BLOOD METABOLOME DURING MENOPAUSE AND ITS ASSOCIATION WITH CARDIOVASCULAR DISEASE RISK
Keywords:
menopause, cardiovascular disease, blood metabolome, lipidomics, metabolomics, lipoproteins, apolipoprotein B, estrogen deficiency, oxidative stress, biomarkers.Abstract
Menopause is accompanied by profound endocrine, metabolic, and biochemical alterations that affect the composition and function of circulating blood. The decline in ovarian estrogen production is associated with changes in lipid metabolism, lipoprotein composition, glucose homeostasis, amino-acid metabolism, fatty-acid oxidation, inflammation, and oxidative stress. These metabolic alterations may contribute substantially to the increasing cardiovascular disease risk observed in women during and after the menopausal transition.This narrative review analyzes current scientific evidence concerning menopause-associated changes in the chemical composition of blood and their relationship with cardiovascular disease. Particular attention is given to alterations in conventional lipid parameters, lipoprotein subclasses, apolipoprotein B, triglyceride-rich lipoproteins, fatty acids, amino acids, glucose-related metabolites, inflammatory biomarkers, and oxidative stress markers. The potential contribution of modern analytical approaches, including nuclear magnetic resonance spectroscopy, mass spectrometry, metabolomics, and lipidomics, is also considered.Available evidence indicates that menopause is associated with a shift toward a more atherogenic circulating biochemical profile, characterized by increased concentrations of low-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and several very-low-density lipoprotein subclasses. At the same time, changes in amino acids, fatty-acid metabolites, ketone bodies, glycerol, and intermediary metabolites indicate that menopause represents a broader metabolic transition rather than an isolated alteration in lipid metabolism.Understanding menopause-associated chemical remodeling of the blood metabolome may contribute to the identification of novel biomarkers for early cardiovascular risk assessment. Integration of conventional biochemical analysis with metabolomic and lipidomic approaches may provide a more comprehensive understanding of cardiovascular disease mechanisms in postmenopausal women.
References
1.Matthews K.A., Crawford S.L., Chae C.U., et al. Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? Archives of Internal Medicine. 2009.
2.Wildman R.P., Colvin A.B., Powell L.H., et al. Associations of endogenous sex hormones with lipids and lipoproteins in postmenopausal women. Journal of Clinical Endocrinology & Metabolism.
3.Anagnostis P., Stevenson J.C., Goulis D.G., et al. Cardiovascular health and the menopause. Best Practice & Research Clinical Endocrinology & Metabolism. 2024.
4.Uddenberg E.R., Safwan N., Saadedine M., et al. Menopause transition and cardiovascular disease risk. Maturitas. 2024;185:107974.
5.Johannesen C.D.L., Langsted A., Nordestgaard B.G., Mortensen M.B. Excess apolipoprotein B and cardiovascular risk in women and men. Journal of the American College of Cardiology. 2024;83:2262–2273.
6.Mozaffarian D., et al. Menopause modulates the circulating metabolome: evidence from a prospective cohort study. 2022.
7.Balasubramanian R., Demler O., Guasch-Ferré M., et al. Metabolomic effects of hormone therapy and associations with coronary heart disease among postmenopausal women. Circulation: Genomic and Precision Medicine. 2020;13:e002977.
8.Anagnostis P., et al. The effect of menopause on lipoprotein(a) concentrations: a systematic review and meta-analysis. Maturitas. 2022.
9.Takebayashi T., et al. Metabolic profiling of charged metabolites in association with menopausal status in Japanese community-dwelling midlife women. Maturitas. 2021.
10.Evaluating the association between amino acid and acylcarnitine profiles and different levels of coronary artery disease risk in postmenopausal women using targeted metabolomics. 2022.
11.Wang Q., Xie B., Fu C., et al. Integrating menopause duration and plasma metabolomics enhances cardiovascular risk stratification in aging women. npj Aging. 2026.
12.Santen R.J., Yue W., Wang J.P., Fan P. Estrogen metabolism and breast cancer. Journal of Steroid Biochemistry and Molecular Biology. 2020;204:105754.
13.Alberti K.G.M.M., Eckel R.H., Grundy S.M., et al. Harmonizing the metabolic syndrome. Circulation. 2009;120:1640–1645.
14.Lovejoy J.C., Champagne C.M., de Jonge L., et al. Increased visceral fat and decreased energy expenditure during menopause. Journal of Clinical Endocrinology & Metabolism. 2008;93:4232–4238.
15.Rose D.P., Vona-Davis L. Biochemical and molecular mechanisms linking obesity and breast cancer. Endocrine-Related Cancer. 2014;21:R365–R384.
